<DOC>
	<DOCNO>NCT00044954</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage cancer cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy donor peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combine total-body irradiation fludarabine donor peripheral stem cell transplantation treat patient hematologic cancer .</brief_summary>
	<brief_title>Total-Body Irradiation , Fludarabine , Peripheral Stem Cell Transplantation Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate duration response patient low-risk hematologic malignancy treat low-dose total-body irradiation ( TBI ) fludarabine follow HLA-matched allogeneic stem cell transplantation follow slow immunosuppression taper donor leukocyte infusion ( DLI ) . - Determine response rate duration response patient high-risk hematologic malignancy treat low-dose TBI fludarabine follow HLA-matched allogeneic stem cell transplantation follow fast immunosuppression taper DLI . - Determine incidence extent graft-versus-host disease , regimen-related toxicity , engraftment patient treat regimen . - Assess quality life patient treat regimen . OUTLINE : This multicenter study . Patients assign 1 2 group ( high-risk v low-risk hematologic malignancy ) . The high-risk group include acute myelogenous leukemia , myelodysplastic syndrome , accelerate phase chronic myelogenous leukemia ( CML ) , second chronic phase CML , non-Hodgkin 's lymphoma . The low-risk group include Hodgkin 's lymphoma , first chronic phase CML , multiple myeloma , chronic lymphocytic leukemia . Patients receive fludarabine IV day -4 -2 . Patients undergo total-body irradiation day 0 follow allogeneic stem cell transplantation . Patients also receive oral mycophenolate mofetil day 0-28 . High-risk patient receive oral cyclosporine twice daily day -2 day 60 . Patients persistent disease , T-cell chimerism , graft-vs-host disease ( GVHD ) day 90 receive 3 dos donor leukocyte infusion ( DLI ) next 4 month . Low-risk patient receive oral cyclosporine twice daily day -2 day 150 . Patients persistent disease , T-cell chimerism , GVHD day 180 receive 3 dos DLI next 4 month . Quality life assess baseline 1 , 3 , 6 , 9 , 12 , 18 , 24 month . Patients follow 1 , 3 , 6 , 9 , 12 month annually 2 year . PROJECTED ACCRUAL : A total 120 patient ( 60 per group ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematologic malignancy : Chronic myelogenous leukemia ( CML ) First second chronic phase Accelerated phase Acute myelogenous leukemia ( AML ) At least second remission First remission allow poorrisk feature present ( complex chromosome karyotype , abnormality chromosome , especially 5 7 , 12p , +13 , +8 , [ 9:11 ] ) Myelodysplastic syndrome ( MDS ) Intermediate highrisk disease prognostic scoring system Multiple myeloma ( MM ) Hodgkin 's lymphoma Second great relapse First relapse allow diseasefree interval less 1 year Ineligible autologous transplantation NonHodgkin 's lymphoma ( NHL ) Grade III follicular large cell ( relapsed one course prior chemotherapy ) Diffuse large cell ( relapsed one course prior chemotherapy ) Mantle cell Chronic lymphocytic leukemia ( CLL ) Relapsed least 1 course prior therapy Must 6 6 HLA A , B , DR identical sibling donor PATIENT CHARACTERISTICS : Age 18 75 patient MM 50 75 patient CML , AML , MDS , Hodgkin 's lymphoma , NHL , CLL 18 49 patient CML , AML , MDS , Hodgkin 's lymphoma , NHL , CLL consider eligible allogeneic bone marrow transplantation ( BMT ) meet institutional criterion standard allogeneic BMT Performance status Zubrod 02 Life expectancy At least 6 month Hematopoietic Not specify Hepatic Bilirubin great 3 mg/dL Renal Creatinine great 2 mg/dL Cardiovascular LVEF least 40 % MUGA echocardiogram Pulmonary DLCO least 50 % predict Other HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No recent history drug alcohol abuse No prior malignancy except basal cell skin cancer No uncontrolled bacterial , viral , fungal , parasitic infection PRIOR CONCURRENT THERAPY : Biologic therapy Prior autologous transplantation allow disease progression occur No prior concurrent tandem autologous transplantation follow nonmyeloablativeallograft protocol Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2005</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>